BriefingSubscribe
BrieflyToldAbout
Breaking
• Democrats sweep the midterms and take both chambers of Congress• Bomb threats divert at least 19 passenger flights across Europe• Wall Street reverses as AI chip stocks sink the Nasdaq• Vance blames the Iran war for the Republican wipeout• OpenAI rolls out faster image model that also makes GIFs• Pungent gas over Mars fissures hints the planet is still volcanically active• Democrats sweep the midterms and take both chambers of Congress• Bomb threats divert at least 19 passenger flights across Europe• Wall Street reverses as AI chip stocks sink the Nasdaq• Vance blames the Iran war for the Republican wipeout• OpenAI rolls out faster image model that also makes GIFs• Pungent gas over Mars fissures hints the planet is still volcanically active
Tech

Drugmaker CEOs Push Back on Silicon Valley’s AI Cure Promises

The Wall Street Journal reports a divide between tech leaders’ ambitions for AI and drugmakers’ skepticism about its ability to cure disease.

BrieflyTold Desk · · 1 min brief

Share𝕏WAf
Illustration · BrieflyTold

The brief

  • ■Drugmaker CEOs are skeptical of Silicon Valley’s promises about AI curing disease.
  • ■AI can help researchers analyze data and identify potential drug candidates.
  • ■Promising treatments still need testing to establish safety and effectiveness.

Why it matters

For Americans hoping for better treatments, AI’s promise does not mean new medicines will reach pharmacies soon or cost less.

Silicon Valley’s promises that artificial intelligence will cure disease are meeting skepticism from drugmaker CEOs, The Wall Street Journal reports. The divide highlights the difference between finding promising scientific leads and producing medicines that work in patients.

AI can help researchers sift through biological data and identify molecules worth investigating. But a promising prediction is not proof that a treatment will be safe or effective in the human body.

New drugs generally must undergo clinical trials and FDA review before they can be marketed in the United States. Even if AI speeds up early research, it does not automatically shorten every development step or guarantee lower prices for patients.

ai drug discoverydrugmaker ceos ai skepticismsilicon valley ai curesai disease treatmentwsj ai drugmakersai medicine development

Sources

  • WSJ
Read the original reporting ↗

More briefs